Robert Nelsen, Director at Juno Therapeutics, holds 0.00 shares in Juno Therapeutics (Ticker: JUNO), holds ― shares in Sienna Biopharmaceuticals (Ticker: SNNAQ), holds 13.53M shares in Vir Biotechnology (Ticker: VIR).
Robert Nelsen latest transaction was an Uninformative Sell of $922.76M.
What was Robert Nelsen's most profitable transaction?
Robert Nelsen’s most profitable transaction was an Informative Buy of KRTX stock on July 2, 2019. The return on the trade was 405.70%.
What is Robert Nelsen's role in Juno Therapeutics?
Robert Nelsen's role in Juno Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.